<DOC>
	<DOCNO>NCT01482065</DOCNO>
	<brief_summary>This research do examine : 1 ) common obstructive sleep apnea ( OSA ) patient non-alcoholic fatty liver disease ( NAFLD ) , 2 ) whether severity OSA related severity NAFLD , 3 ) whether treatment OSA continuous positive airway pressure ( CPAP ) improve NAFLD progression . OSA condition cause repetitive collapse throat tissue sleep lead fall oxygen level sleep disruption . OSA cause obesity , especially fat find neck belly . NAFLD common disease link obesity . NAFLD part disease spectrum , progress steatosis ( fatty liver ) nonalcoholic steatohepatitis ( NASH ) , progressive fibrotic disease , cirrhosis liver-related death occur . Recent evidence patient obstructive sleep apnea ( OSA ) indicate OSA associate NASH . How common OSA patient biopsy-confirmed NAFLD effect OSA treatment CPAP NASH unknown .</brief_summary>
	<brief_title>The Sleep , Liver Evaluation Effective Pressure Study</brief_title>
	<detailed_description>Nonalcoholic fatty liver disease ( NAFLD ) common disease well-established link obesity increasingly prevalent concurrent rise obesity . NAFLD constitute disease spectrum steatosis cirrhosis associate significant morbidity mortality . The pathogenesis NAFLD , especially disease progression , well understood . Obesity insulin resistance play role ' first hit ' leading liver steatosis , mechanism 'second hit ' trigger progression steatohepatitis know . Based Preliminary Data , propose novel hypothesis chronic intermittent hypoxia ( CIH ) patient obstructive sleep apnea ( OSA ) constitute 'second hit ' cause progression NAFLD steatosis nonalcoholic steatohepatitis ( NASH ) , progressive fibrotic disease , cirrhosis liver-related death occur 20 % 12 % patient , respectively . Obstructive sleep apnea ( OSA ) characterize recurrent collapse upper airway sleep , lead CIH . OSA common disease , present 2 % woman 4 % men general US population , increase prevalence 30-60 % obese population . Furthermore , CIH associate multiple metabolic complication OSA independent obesity , include insulin resistance , dyslipidemia , atherosclerosis . Previous work rodent model demonstrate intermittent hypoxia ( IH ) increase : ( 1 ) insulin resistance ; ( 2 ) hepatic steatosis ; ( 3 ) hepatic level Sterol regulatory element-binding protein-1 ( SREBP-1 ) Stearoyl-CoA desaturase ( SCD-1 ) ; ( 4 ) hepatic oxidative stress inflammation Thus , CIH OSA may contribute hepatic steatosis , convert hepatic steatosis steatohepatitis . To address hypothesis , establish impact OSA NASH susceptible cohort obese human subject definitive intraoperative liver biopsy available diagnose stage NAFLD . Recent evidence patient obstructive sleep apnea ( OSA ) indicate OSA associate NASH . Nevertheless , prevalence OSA patient biopsy-confirmed NAFLD unknown effect OSA treatment CPAP NASH never study . Our main hypothesis severity nocturnal intermittent hypoxemia obstructive sleep apnea ( OSA ) associate severity NAFLD . We examine NAFLD severity patient without obstructive sleep apnea examine effect CPAP NAFLD progression patient obstructive sleep apnea . The overall goal determine whether OSA associate NAFLD whether CPAP mitigate NAFLD progression . Our primary hypothesis severity nocturnal intermittent hypoxemia obstructive sleep apnea ( OSA ) associate severity NAFLD . - In Specific Aim # 1 , examine NAFLD severity patient without obstructive sleep apnea . We hypothesize severity NAFLD presence NASH associate presence severity OSA . - In Specific Aim # 2 , examine effect CPAP NAFLD progression patient obstructive sleep apnea . We hypothesize CPAP decrease marker hepatic inflammation ( serum aminotransferase ) patient NAFLD , moderate severe OSA . To address hypothesis , enroll patient Johns Hopkins Medical Institution ( JHMI ) Hepatology clinic diagnosis NAFLD , elevate serum aminotransferase , NAFLD liver biopsy , moderate severe OSA . The effect CPAP marker liver inflammation serum aminotransferase determine , relate CPAP adherence .</detailed_description>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Sleep Apnea , Obstructive</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Age ≥ 21 Diagnosis NAFLD BMI ≥ 30 obesity BMI &gt; 35 &lt; 400lbs No cause liver disease NAFLD ( assessed patient physician survey detail , blood work magnetic resonance imaging ( MRI ) ) Both patient doctor ask identify potential exclusionary condition include : 1 . Patients sickle cell anemia , hemoglobinopathy hemolytic anemias 2 . Known clinical hypersensitivity history asthma allergic respiratory disorder 3 . Advanced renal failure ( currently require dialysis Glomerular Filtration rate &lt; 30cc/min ) 4 . Pregnancy 5 . History CPAP treatment OSA 6 . Recent weight loss ( 6 month ) ≥ 10 % 7 . Current alcohol use &gt; 20 g/day woman &gt; 30 g/day men , prior use ≥ 3 consecutive month previous 5 year assess Lifetime Drinking History Questionnaire Viral hepatitis A , B C 8 . Autoimmune hepatitis 9 . Hemochromatosis 10 . Wilson 's disease 11 . Alpha1antitrypsin deficiency 12 . Primary sclerosing cholangitis 13 . Cirrhosis etiology 14 . History HIV infection and/or HAART therapy 15 . Evidence druginduced liver injury 16 . Use systemic steroid &gt; 10 day prior 6 month 17 . Unstable cardiovascular disease ( decompensated chronic heart failure ( CHF ) , myocardial infarction revascularization procedure , unstable arrhythmia ) 18 . Uncontrolled hypertension BP &gt; 190/110 19 . Daytime hypoxemia oxygen saturation ( SaO2 ) &lt; 90 % 20 . Supplemental oxygen use 21 . Presence contraindication MR examination ( see MRI Safety Screening Sheet ) 22 . History Metal Skull/Eyes 23 . Unable MRI Scan 24 . Severe daytime hypersomnolence define Epworth Sleepiness Score great 10 . 25 . Severe sleep apnea characterize apneahypopnea index great 80 episodes/hour average low SaO2 sleep disorder breathe episodes 80 % . 26 . Work transportation industry driver pilot . 27 . Patients diagnosis sleep apnea active treatment . Exclusions base etiology hepatitis assess query hepatology list patient mention disorder ( # 715 ) test viral hepatitis A , B , C , ferritin , antinuclear antibody ( ANA ) , antineutrophil cytoplasmic antibody ( ANCA ) , antimitochondrial antibody , antismooth muscle antibody ceruloplasmin .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Non Alcoholic Fatty Liver Disease</keyword>
	<keyword>NAFLD</keyword>
	<keyword>Continuous Positive Airway Pressure</keyword>
	<keyword>CPAP</keyword>
	<keyword>CPAP Therapy</keyword>
	<keyword>Apnea Hypopnea Index</keyword>
	<keyword>Non alcoholic steatohepatitis</keyword>
	<keyword>NASH</keyword>
	<keyword>OSA</keyword>
	<keyword>Obstructive Sleep Apnea</keyword>
	<keyword>AHI</keyword>
</DOC>